Main Menu


Dr Anna Minchom

Publications Highlights View all by category

Types of Publications

Journal Articles

Mohamedkhan, S. Hindocha, S. de Boisanger, J. Millard, T. Welsh, L. Rich, P. MacKinnon, A.D. Williams, N. Sharma, B. Rosenfelder, N. Minchom, A. (2024). Contrast Clearance Analysis (CCA) to Assess Viable Tumour following Stereotactic Radiosurgery (SRS) to Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC). Cancers (basel), Vol.16 (6).  show abstract  full text

Gabriel, L. McVeigh, T. Macmahon, S. Avila, Z. Donovan, L. Hunt, I. Draper, A. Minchom, A. Popat, S. Davidson, M. Bhosle, J. Milner Watts, C. Hubank, M. Yuan, L. O'Brien, M. (2024). Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family. Lung cancer, Vol.191, p. 107543.  show abstract

Viteri, S. Minchom, A. Bazhenova, L. Ou, S.-. Bauml, J.M. Shell, S.A. Schaffer, M. Gu, J. Rose, J.B. Curtin, J.C. Mahadevia, P. Girard, N. (2023). Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets. Mol oncol, Vol.17 (2), pp. 230-237.  show abstract

Wu, X. Kumar, R. Milner-Watts, C. Walder, D. Battisti, N.M. Minchom, A. Bhosle, J. O'Brien, M.E. (2023). The Predictive Value of the G8 Questionnaire in Older Patients with Lung Cancer or Mesothelioma before Systemic Treatment. Clin oncol (r coll radiol), Vol.35 (2), pp. e163-e172.  show abstract

Pant, S. Schuler, M. Iyer, G. Witt, O. Doi, T. Qin, S. Tabernero, J. Reardon, D.A. Massard, C. Minchom, A. Lugowska, I. Carranza, O. Arnold, D. Gutierrez, M. Winter, H. Stuyckens, K. Crow, L. Najmi, S. Hammond, C. Thomas, S. Santiago-Walker, A. Triantos, S. Sweiti, H. Loriot, Y. RAGNAR Investigators, (2023). Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet oncol, Vol.24 (8), pp. 925-935.  show abstract

Cho, B.C. Kim, D.-. Spira, A.I. Gomez, J.E. Haura, E.B. Kim, S.-. Sanborn, R.E. Cho, E.K. Lee, K.H. Minchom, A. Lee, J.-. Han, J.-. Nagasaka, M. Sabari, J.K. Ou, S.-. Lorenzini, P. Bauml, J.M. Curtin, J.C. Roshak, A. Gao, G. Xie, J. Thayu, M. Knoblauch, R.E. Park, K. (2023). Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Nat med, Vol.29 (10), pp. 2577-2585.  show abstract

Alger, E. Minchom, A. Lee Aiyegbusi, O. Schipper, M. Yap, C. (2023). Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological review. Eclinicalmedicine, Vol.64, p. 102228.  show abstract  full text

Rannikko, J.H. Verlingue, L. de Miguel, M. Pasanen, A. Robbrecht, D. Skytta, T. Iivanainen, S. Shetty, S. Ma, Y.T. Graham, D.M. Arora, S.P. Jaakkola, P. Yap, C. Xiang, Y. Mandelin, J. Karvonen, M.K. Jalkanen, J. Karaman, S. Koivunen, J.P. Minchom, A. Hollmén, M. Bono, P. (2023). Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial. Cell rep med, Vol.4 (12), p. 101307.  show abstract  full text

Coker, E.A. Stewart, A. Ozer, B. Minchom, A. Pickard, L. Ruddle, R. Carreira, S. Popat, S. O'Brien, M. Raynaud, F. de Bono, J. Al-Lazikani, B. Banerji, U. (2022). Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes. Mol cancer ther, Vol.21 (6), pp. 1020-1029.  show abstract  full text

Banerjee, S. Michalarea, V. Ang, J.E. Ingles Garces, A. Biondo, A. Funingana, I.-. Little, M. Ruddle, R. Raynaud, F. Riisnaes, R. Gurel, B. Chua, S. Tunariu, N. Porter, J.C. Prout, T. Parmar, M. Zachariou, A. Turner, A. Jenkins, B. McIntosh, S. Ainscow, E. Minchom, A. Lopez, J. de Bono, J. Jones, R. Hall, E. Cook, N. Basu, B. Banerji, U. (2022). A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer. Clin cancer res, Vol.28 (21), pp. 4634-4641.  show abstract  full text

Lai-Kwon, J. Vanderbeek, A.M. Minchom, A. Lee Aiyegbusi, O. Ogunleye, D. Stephens, R. Calvert, M. Yap, C. (2022). Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum. Oncologist, Vol.27 (9), pp. 768-777.  show abstract  full text

Stapleton, S.E. Darlington, A.-. Minchom, A. Pal, A. Raynaud, F. Wiseman, T. (2022). Assessing cognitive toxicity in early phase trials - What are we missing?. Psychooncology, Vol.31 (3), pp. 405-415.  show abstract

Cui, W. Milner-Watts, C. McVeigh, T.P. Minchom, A. Bholse, J. Davidson, M. Yousaf, N. MacMahon, S. Mugalaasi, H. Gunapala, R. Lee, R. George, A. Popat, S. O'Brien, M. (2022). A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. Lung cancer, Vol.165, pp. 34-42.  show abstract

Minchom, A. Viteri, S. Bazhenova, L. Gadgeel, S.M. Ou, S.-. Trigo, J. Bauml, J.M. Backenroth, D. Bhattacharya, A. Li, T. Mahadevia, P. Girard, N. (2022). Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung cancer, Vol.168, pp. 74-82.  show abstract

Papadatos-Pastos, D. Yuan, W. Pal, A. Crespo, M. Ferreira, A. Gurel, B. Prout, T. Ameratunga, M. Chénard-Poirier, M. Curcean, A. Bertan, C. Baker, C. Miranda, S. Masrour, N. Chen, W. Pereira, R. Figueiredo, I. Morilla, R. Jenkins, B. Zachariou, A. Riisnaes, R. Parmar, M. Turner, A. Carreira, S. Yap, C. Brown, R. Tunariu, N. Banerji, U. Lopez, J. de Bono, J. Minchom, A. (2022). Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. J immunother cancer, Vol.10 (6).  show abstract  full text

Cui, W. Milner-Watts, C. O'Sullivan, H. Lyons, H. Minchom, A. Bhosle, J. Davidson, M. Yousaf, N. Scott, S. Faull, I. Kushnir, M. Nagy, R. O'Brien, M. Popat, S. (2022). Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur j cancer, Vol.171, pp. 44-54.  show abstract  full text

Castagnoli, F. Doran, S. Lunn, J. Minchom, A. O'Brien, M. Popat, S. Messiou, C. Koh, D.-. (2022). Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. Plos one, Vol.17 (7), p. e0270950.  show abstract  full text

Lai-Kwon, J. Tiu, C. Pal, A. Khurana, S. Minchom, A. (2021). Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective. Crit rev oncol hematol, Vol.159, p. 103225.  show abstract

Joshi, K. Muhith, A. Obeid, M. Milner-Watts, C. Yousaf, N. Popat, S. Davidson, M. Bhosle, J. O'Brien, M. Minchom, A. (2021). Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. Lung cancer, Vol.156, pp. 147-150.  show abstract  full text

Pal, A. Stapleton, S. Yap, C. Lai-Kwon, J. Daly, R. Magkos, D. Baikady, B.R. Minchom, A. Banerji, U. De Bono, J. Karikios, D. Boyle, F. Lopez, J. (2021). Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT). Bmj open, Vol.11 (9), p. e049217.  show abstract  full text

Virtakoivu, R. Rannikko, J.H. Viitala, M. Vaura, F. Takeda, A. Lönnberg, T. Koivunen, J. Jaakkola, P. Pasanen, A. Shetty, S. de Jonge, M.J. Robbrecht, D. Ma, Y.T. Skyttä, T. Minchom, A. Jalkanen, S. Karvonen, M.K. Mandelin, J. Bono, P. Hollmén, M. (2021). Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clinical cancer research : an official journal of the american association for cancer research, Vol.27 (15), pp. 4205-4220.  show abstract

Manickavasagar, T. Yuan, W. Carreira, S. Gurel, B. Miranda, S. Ferreira, A. Crespo, M. Riisnaes, R. Baker, C. O'Brien, M. Bhosle, J. Popat, S. Banerji, U. Lopez, J. de Bono, J. Minchom, A. (2021). HER3 expression and MEK activation in non-small-cell lung carcinoma. Lung cancer manag, Vol.10 (2), p. LMT48.  show abstract  full text

Tiu, C. Shinde, R. Pal, A. Biondo, A. Lee, A. Tunariu, N. Jhanji, S. Grover, V. Tatham, K. Gruber, P. Banerji, U. De Bono, J.S. Nicholson, E. Minchom, A.R. Lopez, J.S. (2021). A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy. J immunother precis oncol, Vol.4 (4), pp. 189-195.  show abstract  full text

Lai-Kwon, J. Yin, Z. Minchom, A. Yap, C. (2021). Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials gov. Cancer med, Vol.10 (22), pp. 7943-7957.  show abstract  full text

Bazhenova, L. Minchom, A. Viteri, S. Bauml, J.M. Ou, S.-. Gadgeel, S.M. Trigo, J.M. Backenroth, D. Li, T. Londhe, A. Mahadevia, P. Girard, N. (2021). Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung cancer, Vol.162, pp. 154-161.  show abstract

Curcean, S. Cheng, L. Picchia, S. Tunariu, N. Collins, D. Blackledge, M. Popat, S. O'Brien, M. Minchom, A. Leach, M.O. Koh, D.-. (2021). Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations. Jto clin res rep, Vol.2 (12), p. 100253.  show abstract  full text

Minchom, A. Tan, A.C. Massarelli, E. Subbiah, V. Boni, V. Robinson, B. Wirth, L.J. Hess, L.M. Jen, M. Kherani, J. Olek, E. McCoach, C.E. (2021). Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion‐Positive Non‐small Cell Lung Cancer in the Phase 1/2 LIBRETTO ‐001 Trial. The oncologist, .

Biondo, A. Pal, A. Riisnaes, R. Shinde, R. Tiu, C. Lockie, F. Baker, C. Bertan, C. Crespo, M. Ferreira, A. Pereira, R. Figueiredo, I. Miranda, S. Gurel, B. Carreira, S. Banerji, U. de Bono, J. Lopez, J. Tunariu, N. Minchom, A. (2021). Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience. Cancer treat res commun, Vol.27, p. 100309.  show abstract  full text

Hindocha, S. Campbell, D. Ahmed, M. Giorgakoudi, K. Sharma, B. Yousaf, N. Molyneaux, P. Hunter, B. Kalsi, H. Cui, W. Davidson, M. Bhosle, J. Minchom, A. Locke, I. McDonald, F. O'Brien, M. Popat, S. Lee, R.W. (2021). Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications. Front med (lausanne), Vol.8, p. 764563.  show abstract  full text

Minchom, A. Yuan, W. Crespo, M. Gurel, B. Figueiredo, I. Wotherspoon, A. Miranda, S. Riisnaes, R. Ferreira, A. Bertan, C. Pereira, R. Clarke, M. Baker, C. Ang, J.E. Fotiadis, N. Tunariu, N. Carreira, S. Popat, S. O'Brien, M. Banerji, U. de Bono, J. Lopez, J. (2020). Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. J immunother cancer, Vol.8 (1).  show abstract  full text

Page, S. Milner-Watts, C. Perna, M. Janzic, U. Vidal, N. Kaudeer, N. Ahmed, M. McDonald, F. Locke, I. Minchom, A. Bhosle, J. Welsh, L. O'Brien, M. (2020). Systemic treatment of brain metastases in non-small cell lung cancer. Eur j cancer, Vol.132, pp. 187-198.  show abstract

Tiu, C. Shinde, R. Yap, C. Rao Baikady, B. Banerji, U. Minchom, A.R. de Bono, J.S. Lopez, J.S. (2020). A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. Lancet oncol, Vol.21 (7), pp. 889-891.  full text

Collins, D.C. Sundar, R. Constantinidou, A. Dolling, D. Yap, T.A. Popat, S. O'Brien, M.E. Banerji, U. de Bono, J.S. Lopez, J.S. Tunariu, N. Minchom, A. (2020). Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. Bmc cancer, Vol.20 (1), p. 1210.  show abstract  full text

Guo, C. Chénard-Poirier, M. Roda, D. de Miguel, M. Harris, S.J. Candilejo, I.M. Sriskandarajah, P. Xu, W. Scaranti, M. Constantinidou, A. King, J. Parmar, M. Turner, A.J. Carreira, S. Riisnaes, R. Finneran, L. Hall, E. Ishikawa, Y. Nakai, K. Tunariu, N. Basu, B. Kaiser, M. Lopez, J.S. Minchom, A. de Bono, J.S. Banerji, U. (2020). Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet oncol, Vol.21 (11), pp. 1478-1488.  show abstract  full text

Terbuch, A. Tiu, C. Candilejo, I.M. Scaranti, M. Curcean, A. Bar, D. Estevez Timon, M. Ameratunga, M. Ang, J.E. Ratoff, J. Minchom, A.R. Banerji, U. de Bono, J.S. Tunariu, N. Lopez, J.S. (2020). Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. Clin cancer res, Vol.26 (18), pp. 4805-4813.  show abstract  full text

Cui, W. Yousaf, N. Bhosle, J. Minchom, A. Nicholson, A.G. Ahmed, M. McDonald, F. Locke, I. Lee, R. O'Brien, M. Popat, S. (2020). Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience. Cancer treat res commun, Vol.25, p. 100261.  show abstract  full text

Cojocaru, E. Scaranti, M. Minchom, A. (2019). Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. Journal of immunotherapy and precision oncology, Vol.2 (2), pp. 23-35.  show abstract

Moss, C.A. Cojocaru, E. Hanwell, J. Ward, S. Xu, W. van Zyl, M. O'Leary, L. de Bono, J.S. Banerji, U. Kaye, S.B. Minchom, A. George, A.J. Lopez, J. McVeigh, T.P. (2019). Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services. Eur j cancer, Vol.114, pp. 97-106.  show abstract  full text

Georgiou, A. Minchom, A. O'Brien, M. (2019). Comment on 'Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer'-No support for de-escalation of immunotherapy. Eur j cancer, Vol.115, pp. 24-26.

Stewart, A. Coker, E.A. Pölsterl, S. Georgiou, A. Minchom, A.R. Carreira, S. Cunningham, D. O'Brien, M.E. Raynaud, F.I. de Bono, J.S. Al-Lazikani, B. Banerji, U. (2019). Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. Mol cancer ther, Vol.18 (8), pp. 1396-1404.  show abstract  full text

Mak, D.W. Li, S. Minchom, A. (2019). Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer. Eur j cancer, Vol.119, pp. 132-150.  show abstract

Georgiou, A. Khakoo, S. Edwards, P. Minchom, A. Kouvelakis, K. Kalaitzaki, E. Nobar, N. Calamai, V. Ifijen, M. Husson, O. Watkins, D. Rao, S. Chau, I. Cunningham, D. Starling, N. (2019). Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. Cancers (basel), Vol.11 (10).  show abstract  full text

Minchom, A. Mak, D. Gunapala, R. Walder, D. Kumar, R. Yousaf, N. Hodgkiss, A. Bhosle, J. Popat, S. O'Brien, M.E. (2019). A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma. Plos one, Vol.14 (11), p. e0225509.  show abstract  full text

Minchom, A. Aversa, C. Lopez, J. (2018). Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther adv med oncol, Vol.10, p. 1758835918786658.  show abstract  full text

Minchom, A. Thavasu, P. Ahmad, Z. Stewart, A. Georgiou, A. O'Brien, M.E. Popat, S. Bhosle, J. Yap, T.A. de Bono, J. Banerji, U. (2017). A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. Plos one, Vol.12 (10), p. e0186106.  show abstract  full text

Kumar, R. Lu, S.K. Minchom, A. Sharp, A. Davidson, M. Gunapala, R. Yap, T.A. Bhosle, J. Popat, S. O'Brien, M.E. (2016). A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer chemother pharmacol, Vol.77 (2), pp. 375-383.  show abstract

Minchom, A. Punwani, R. Filshie, J. Bhosle, J. Nimako, K. Myerson, J. Gunapala, R. Popat, S. O'Brien, M.E. (2016). A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma. Eur j cancer, Vol.61, pp. 102-110.  show abstract

Puglisi, M. Stewart, A. Thavasu, P. Frow, M. Carreira, S. Minchom, A. Punwani, R. Bhosle, J. Popat, S. Ratoff, J. de Bono, J. Yap, T.A. O''Brien, M. Banerji, U. (2016). Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. Oncology, Vol.90 (5), pp. 280-288.  show abstract  full text

Minchom, A. Yu, K.C. Bhosle, J. O'Brien, M. (2014). The diagnosis and treatment of brain metastases in EGFR mutant lung cancer. Cns oncol, Vol.3 (3), pp. 209-217.  show abstract  full text

Minchom, A.R. Saksornchai, K. Bhosle, J. Gunapala, R. Puglisi, M. Lu, S.K. Nimako, K. Coward, J. Yu, K.C. Bordi, P. Popat, S. O'Brien, M.E. (2014). An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity. Bmj open respir res, Vol.1 (1), p. e000061.  show abstract

Young, K. Minchom, A. Larkin, J. (2012). BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future oncol, Vol.8 (5), pp. 499-507.  show abstract

Minchom, A. Young, K. Larkin, J. (2011). Ipilimumab: showing survival benefit in metastatic melanoma. Future oncol, Vol.7 (11), pp. 1255-1264.  show abstract

Minchom, A. Chan, S. Melia, W. Shah, R. (2010). An unusual case of pancreatic cancer with leptomeningeal infiltration. J gastrointest cancer, Vol.41 (2), pp. 107-109.  show abstract

Minchom, A. Jones, R.L. Fisher, C. Al-Muderis, O. Ashley, S. Scurr, M. Karavasilis, V. Judson, I.R. (2010). Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma, Vol.2010, p. 264360.  show abstract

Bowcock, S.J. Minchom, A. Yates, L.R. Ryali, M.M. (2008). Ultra low dose thalidomide in elderly patients with myeloma. Br j haematol, Vol.141 (1), pp. 120-122.


Minchom, A.R.Krebs, M.G.Cho, B.C.Lee, S.-.Leighl, N.B.O'Neil, B.Sabari, J.K.Kudgus-Lokken, R.Alhadab, A.Haddish-Berhane, N.Zemlickis, D.Mitselos, A.Berkay, E.Bauml, J.M.Knoblauch, R.E.Hellemans, P.Johnson, M.L. (2023). Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study-Updated safety and identification of the recommended phase 2 dose, Presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago. JOURNAL OF CLINICAL ONCOLOGY, Vol.41 (16), p. 1.

Elamin, Y.Y.Nagasaka, M.Shum, E.Bazhenova, L.Camidge, D.R.Cho, B.C.Felip, E.Goto, K.Lin, C.-.Piotrowska, Z.Planchard, D.Rotow, J.K.Spigel, D.R.Tan, D.S.Yoshida, T.Minchom, A.R.De langen, A.Kato, T.Zalutskaya, A.Reckamp, K.L. (2023). BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study, Presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago. JOURNAL OF CLINICAL ONCOLOGY, Vol.41 (16), p. 1.

Krebs, M.Spira, A.I.Cho, B.C.Besse, B.Goldman, J.W.Janne, P.A.Ma, Z.Mansfield, A.S.Minchom, A.R.Ou, S.-.Salgia, R.Wang, Z.Perez, C.L.Gao, G.Curtin, J.C.Roshak, A.Schnepp, R.W.Thayu, M.Knoblauch, R.Lee, C.K. (2022). Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study., Presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK. JOURNAL OF CLINICAL ONCOLOGY, Vol.40 (16), p. 1.

Girard, N.Minchom, A.Ou, S.-.Gadgeel, S.M.Trigo, J.Viteri, S.Bauml, J.M.Londhe, A.Mahadevia, P.Bazhenova, L. (2022). Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors., United States. Clin Lung Cancer, Vol.23 (7), pp.571-577.

Krebs, M.G.Johnson, M.L.Cho, B.C.Lee, S.-.Kudgus-Lokken, R.Zemlickis, D.Mitselos, A.Berkay, E.Bauml, J.M.Knoblauch, R.E.Hellemans, P.Minchom, A. (2022). Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study., Presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans. CANCER RESEARCH, Vol.82 (12), p. 2.

In this section